In the framework of the crowdfunding campaign #MultiplesMotivos, Fundación GAEM and Bionure are organizing next Tuesday, July 9, the webinar New neuroprotectant treatments and combined therapies. In the session, that will start at 6:30PM (Spanish time), Dr Pablo Villoslada, researcher at IDIBAPS-Hospital Clinic of Barcelona and Stanford University, CSO and chair of SAB of Bionure and company’s co-funder, will talk about last developments in neuroprotectant treatments research and the mechanism of action of BN201, Bionure’s lead compound.

The small molecule BN201 was identified by screening combinatorial chemical libraries using in vitro assays and has demonstrated that it is able to promote neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro, and the myelination of new axons. In vivo, BN201 prevents axonal and neuronal loss, and it promotes remyelination in models of multiple sclerosis, chemically induced demyelination, and glaucoma.

During the webinar, Dr Lucia Septien, Bionure’s CMO, will present the current stage of clinical development of BN201.

For more information and register click here.

Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Both Genetics and Environment Play a Rol...

by ISGlobal - Instituto de Salud Global de Barcelona

A study with samples from more than 1000 European children analyses fo...

Photos Stream